NASDAQ:ACIU AC Immune Q1 2025 Earnings Results & Report $2.50 -0.05 (-1.96%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$2.50 0.00 (0.00%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. AC Immune beat analyst earnings expectations but missed on revenue in its Q1 2025 results, released April 30, 2025. The company reported EPS of -$0.21 versus the -$0.22 consensus estimate, while revenue of $1.12 million fell short of the $1.99 million estimate by $0.87 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateApril 30, 2025TimeBefore Market OpensConference Call DateApril 29, 2025Conference Call6:00 PM ET AC Immune EPS ResultsActual EPS-$0.21Consensus EPS -$0.22Beat/MissBeat by +$0.01One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersAC Immune Revenue ResultsActual Revenue$1.12 millionExpected Revenue$1.99 millionBeat/MissMissed by -$872.00 thousandYoY Revenue GrowthN/AUpcoming EarningsAC Immune's Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 4, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) AC Immune Q1 2025 Earnings FAQ Did AC Immune beat earnings estimates for Q1 2025? AC Immune (NASDAQ:ACIU) reported earnings of -$0.21 per share for Q1 2025, beating the consensus estimate of -$0.22. The report was announced on Wednesday, April 30, 2025. What was AC Immune's revenue for Q1 2025? AC Immune reported revenue of $1.12 million for Q1 2025, against a consensus estimate of $1.99 million. When is AC Immune's next earnings date? AC Immune's next earnings date is estimated for Tuesday, November 3, 2026. MarketBeat tracks confirmed and estimated earnings dates for AC Immune on the company's earnings history page. AC Immune Earnings HeadlinesAC Immune (NASDAQ:ACIU) Stock Has Consensus Target Price of $7.50 According to BrokeragesOctober 6, 2026 | americanbankingnews.comAC Immune Adds Tom Graney to Board Following Extraordinary General MeetingOctober 2, 2026 | tipranks.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)AC Immune: Buy Continued ACI-7104 Progress, PD, And Pipeline ExpansionsSeptember 24, 2026 | seekingalpha.comAC Immune Reports Positive Safety and Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104September 24, 2026 | marketscreener.comMFein Reiterates Buy on AC Immune as VacSYn Phase 2 Data Validate Platform; $12 Price Target MaintainedSeptember 24, 2026 | tipranks.comSee More AC Immune Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like AC Immune? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AC Immune and other key companies, straight to your email. Email Address About AC ImmuneAC Immune (NASDAQ:ACIU) SA (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland. The company develops precision medicines and diagnostic products for neurodegenerative diseases, with a primary focus on Alzheimer’s disease and other conditions involving the abnormal accumulation or misfolding of proteins in the brain. AC Immune’s research platform includes SupraAntigen, which is designed to generate antibodies against pathological forms of proteins, and Morphomer, a technology focused on identifying small molecules that can target and potentially prevent protein misfolding. Its pipeline has included investigational vaccines, antibodies and small-molecule therapies directed at amyloid-beta, tau and other disease-associated proteins. Founded in 2003, AC Immune conducts research and clinical development through international collaborations and partnerships. Its programs have been evaluated in clinical studies across multiple geographies, including North America and Europe. The company is led by Chief Executive Officer Andrea Pfeifer, who has guided its development as a neuroscience-focused biotechnology company.View AC Immune ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
